Alpha 1 lung disease such as Alpha-1 antitrypsin deficiency can cause lung or liver issues. Alpha-1 antitrypsin is a protein produced in the liver that helps protect the lungs from the damaging effects of other proteins. People with AAT deficiency produce less functional AAT than normal, which can lead to lung or liver problems. Symptoms of lung disease caused by AAT deficiency may include shortness of breath, a persistent dry cough, frequent lung infections like pneumonia or bronchitis. The global Alpha 1 Lung Disease Market comprises of therapeutics utilized to treat Alpha-1 antitrypsin deficiency that impede the damage caused to lungs due to decreased levels of AAT protein. Treatment options include augmentation therapy, which involves weekly intravenous infusions of plasma-derived AAT protein to balance levels in the blood and lungs.

The global Alpha 1 Lung Disease Market is estimated to be valued at US$ 4.99 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/alpha-1-lung-disease-market-6188

Market key trends:

One of the major trends in the alpha 1 lung disease market is the significant increase in research and development activities pertaining to orphan disease treatments. Alpha-1 antitrypsin deficiency is considered an orphan disease due to its low prevalence rate. However, the potentially serious complications associated with the disease have driven increased research efforts from pharmaceutical companies. There is an ongoing clinical trial by Arrowhead Pharmaceuticals evaluating ARO-AAT, which is a potential RNAi therapeutic aimed at increasing endogenous AAT expression. Moreover, companies are developing new formulations and delivery methods such as inhalable treatments to improve efficacy and convenience of augmentation therapy. This significant RD focus on developing advanced treatment solutions for alpha 1 lung disease is expected to drive the market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The high costs involved in RD for developing treatment options for rare diseases like Alpha 1 Lung Disease acts as a barrier for new players.
Bargaining power of buyers: The availability of limited treatment options gives buyers less bargaining power against existing players in the market.
Bargaining power of suppliers: The specialized nature of drugs and therapies required for Alpha 1 Lung Disease mean that suppliers have some bargaining power over prices.
Threat of new substitutes: There is limited threat currently given the lack of alternatives for treating this rare genetic condition.
Competitive rivalry: The market currently sees competition between major pharmaceutical players to develop more effective drugs.

Key Takeaways

The global Alpha 1 Lung Disease market is expected to witness high growth. Regional analysis related content comprises Regional analysis related content The North America region currently dominates the Alpha 1 Lung Disease market due to high awareness and advanced healthcare facilities. Asia Pacific is expected to grow at the fastest pace during the forecast period owing to rising healthcare investments in countries like China and India.

Key players related content comprises Key players related content Key players operating in the Alpha 1 Lung Disease market are AstraZeneca, Boehringer Ingelheim, Roche , Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences , Eli Lilly, AbbVie, Johnson Johnson, Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals. Major players are focusing on developing new targets and innovative treatment options to expand their product portfolios and strengthen their market position.